Encorafenib plus Binimetinib in Patients with locally advanced, inoperable, or metastatic BRAFV600 mutated Melanoma: First Data from the multicenter, multinational, prospective, non-interventional Longitudinal Study BERINGMELANOM.

Erika Richtig; D Debus; R Stadler; C Holler; JS Utikal; R Dummer; S Haferkamp; R von Moos; O Michielin; D Schadendorf

Encorafenib plus Binimetinib in Patients with locally advanced, inoperable, or metastatic BRAFV600 mutated Melanoma: First Data from the multicenter, multinational, prospective, non-interventional Longitudinal Study BERINGMELANOM.

Erika Richtig
, D Debus
, R Stadler
, C Holler
, JS Utikal
, R Dummer
, S Haferkamp
, R von Moos
, O Michielin
, D Schadendorf

Department of Dermatology and Venereology

Research output: Contribution to journal › Conference abstract

Original language	German (Austria)
Journal	JDDG - Journal of the German Society of Dermatology
Publication status	Published - 2020
Event	30. Deutscher Hautkrebskongress - Ludwigshafen, Germany Duration: 9 Sept 2020 → 12 Sept 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Branches of science

302 Clinical Medicine

Links

Web of Science

Encorafenib plus Binimetinib in Patients with locally advanced, inoperable, or metastatic BRAFV600 mutated Melanoma: First Data from the multicenter, multinational, prospective, non-interventional Longitudinal Study BERINGMELANOM.
Richtig, E. (Author), Debus, D. (Author), Stadler, R. (Author), Holler, C. (Author), Utikal, J. (Author), Dummer, R. (Author), Haferkamp, S. (Author), von Moos, R. (Author), Michielin, O. (Author) & Schadendorf, D. (Author)
2020
Activity: Talk, presentation or poster › Scientific talk or presentation › On site

Cite this

Richtig, E., Debus, D., Stadler, R., Holler, C., Utikal, JS., Dummer, R., Haferkamp, S., von Moos, R., Michielin, O., & Schadendorf, D. (2020). Encorafenib plus Binimetinib in Patients with locally advanced, inoperable, or metastatic BRAFV600 mutated Melanoma: First Data from the multicenter, multinational, prospective, non-interventional Longitudinal Study BERINGMELANOM. JDDG - Journal of the German Society of Dermatology.

@article{81084290bc3a4bb5b85cb85a53c31e2f,

title = "Encorafenib plus Binimetinib in Patients with locally advanced, inoperable, or metastatic BRAFV600 mutated Melanoma: First Data from the multicenter, multinational, prospective, non-interventional Longitudinal Study BERINGMELANOM.",

author = "Erika Richtig and D Debus and R Stadler and C Holler and JS Utikal and R Dummer and S Haferkamp and \{von Moos\}, R and O Michielin and D Schadendorf",

year = "2020",

language = "Deutsch ({\"O}sterreich)",

journal = "JDDG - Journal of the German Society of Dermatology",

issn = "1610-0379",

publisher = "Wiley-Blackwell Publishing Ltd",

note = "30. Deutscher Hautkrebskongress, ADO 30 ; Conference date: 09-09-2020 Through 12-09-2020",

}

Richtig, E, Debus, D, Stadler, R, Holler, C, Utikal, JS, Dummer, R, Haferkamp, S, von Moos, R, Michielin, O & Schadendorf, D 2020, 'Encorafenib plus Binimetinib in Patients with locally advanced, inoperable, or metastatic BRAFV600 mutated Melanoma: First Data from the multicenter, multinational, prospective, non-interventional Longitudinal Study BERINGMELANOM.', JDDG - Journal of the German Society of Dermatology.

Encorafenib plus Binimetinib in Patients with locally advanced, inoperable, or metastatic BRAFV600 mutated Melanoma: First Data from the multicenter, multinational, prospective, non-interventional Longitudinal Study BERINGMELANOM. / Richtig, Erika; Debus, D; Stadler, R et al.
In: JDDG - Journal of the German Society of Dermatology, 2020.

Research output: Contribution to journal › Conference abstract

TY - JOUR

T1 - Encorafenib plus Binimetinib in Patients with locally advanced, inoperable, or metastatic BRAFV600 mutated Melanoma: First Data from the multicenter, multinational, prospective, non-interventional Longitudinal Study BERINGMELANOM.

AU - Richtig, Erika

AU - Debus, D

AU - Stadler, R

AU - Holler, C

AU - Utikal, JS

AU - Dummer, R

AU - Haferkamp, S

AU - von Moos, R

AU - Michielin, O

AU - Schadendorf, D

PY - 2020

Y1 - 2020

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:000562279300170

M3 - Konferenzabstract

SN - 1610-0379

JO - JDDG - Journal of the German Society of Dermatology

JF - JDDG - Journal of the German Society of Dermatology

T2 - 30. Deutscher Hautkrebskongress

Y2 - 9 September 2020 through 12 September 2020

ER -

Encorafenib plus Binimetinib in Patients with locally advanced, inoperable, or metastatic BRAFV600 mutated Melanoma: First Data from the multicenter, multinational, prospective, non-interventional Longitudinal Study BERINGMELANOM.

UN SDGs

Branches of science

Links

Activities

Encorafenib plus Binimetinib in Patients with locally advanced, inoperable, or metastatic BRAFV600 mutated Melanoma: First Data from the multicenter, multinational, prospective, non-interventional Longitudinal Study BERINGMELANOM.

Cite this